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Vinyl chloride and the liverq
Morris Sherman*
Department of Medicine, University of Toronto, Rm. # NCSB 11C 1252, 585 University Avenue, Toronto, Ont., Canada M5G 2N2Vinyl chloride monomer is a known cause of angiosarcoma of the liver. It also has other toxic eﬀects on the liver, and it
has recently been suggested that exposure to vinyl chloride also causes hepatocellular carcinoma. However, the data on
which this conclusion is based is incomplete. There is inadequate ascertainment of unequivocal diagnoses. In the largest
studies lack of data meant that confounding diseases such as viral hepatitis or alcoholic liver disease could not be assessed.
At best, the increase in risk is minimal, based on more than 22,000 exposed workers and more than 640,000 person years of
observation.
However, based on the available data the hypothesis that vinyl chloride causes or contributes to the development of hepa-
tocellular carcinoma remains unproven.
 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Vinyl chloride monomer (VCM) is a colourless gas at
room temperature. Polyvinyl chloride (PVC) is a poly-
merized form of vinyl chloride that is extensively used
in the plastics industry. VCM does not occur naturally,
and thus is found almost exclusively in factories making
PVC. Small amounts of VCM are found in ﬁnished plas-
tic products, curiously, it is to be found in highest con-
centration in vinyl records. VCM is also present in
cigarette smoke; the amount depends on the chloride
concentration of the tobacco. VCM has not been identi-
ﬁed in food, pharmaceuticals or cosmetic products in
recent years [1].0168-8278/$36.00  2009 European Association for the Study of the Liver.
doi:10.1016/j.jhep.2009.09.012
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the USA for more than 70 years [2]. In 2001 about 6.2
million tones were produced [3]. Around the world
about 35 million tons were produced in 2005 [4]. About
40,000 workers in Europe and 80,000 workers in the
USA have been potentially exposed to VCM up to
1997 [5].
Detailed descriptions of toxicity ﬁrst appeared in the
1970s. VCM is causally associated with the development
of a form of non-cirrhotic portal hypertension related to
sinusoidal endothelial damage, and to angiosarcoma of
the liver (ASL). More recently it has been suggested that
VCM also causes hepatocellular carcinoma (HCC). This
review was triggered (but not sponsored) by a workshop
convened by the European Council of Vinyl Manufac-
turer’s to examine the causal relationship between expo-
sure to VCM and the development of HCC. It is
important that the strength of the association between
VCM exposure and HCC be evaluated. Unlike angio-
sarcoma, HCC is not a rare cancer. In fact, it is increas-
ing in incidence in many countries. Therefore even if
VCM has no role in the development of HCC some
VCM workers are likely to develop HCC. In many cases
the main etiologic agent of the HCC, namely chronic
hepatitis B or C, will be easily identiﬁable, but inPublished by Elsevier B.V. All rights reserved.
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tes or non-alcoholic fatty liver disease it will not be easy
to document the pre-existing liver disease that was
responsible for the development of HCC. This clearly
demonstrates the need to conﬁrm whether VCM causes
or contributes to HCC. This issue has been addressed by
the International Agency for Research in Cancer
(IARC) which has concluded that there is suﬃcient evi-
dence that VCM is a cause of HCC [6].
As the toxicity of VCM was recognized the industry
took steps to protect workers, resulting in a progres-
sively decreasing measured concentration of VCM in
workshop areas. In 1978 the European producers of
VCM established a registry of cases of angiosarcoma
[7]. This registry has shown a decreasing annual number
of cases, with no new case in whom exposure began after
1972. The register currently contains 231 cases. Most of
the cases come from Europe and North America, with
few coming from Eastern Europe or China, both pro-
ducers of VCM. This is likely due to inadequate report-
ing, rather than more stringent safety precautions in
those parts of the world. The annual incidence of ASL
in workers from the USA included in the registry was
0.014/100,000. There is a decreasing trend in reported
cases over time, suggesting that the industry has been
successful in reducing worker exposure. Nonetheless,
because the mean latency between exposure and the
development of ASL in the registry was 27 years addi-
tional cases of VCM-related ASL might still be
observed. Recorded levels of human exposure in VCM
factories vary widely. Prior to environmental controls
being instituted exposure levels were high, measured
up to 7800 mg/m3 [8] (10 ppm equals about 26 mg/m3).
In recent years, in countries with strict and strictly
enforced environmental standards current exposure lev-
els are usually less than 1 mg/m3 [9]. However, in coun-
tries where environmental controls are less strict
relatively high levels of exposure (e.g., up to 800 mg/
m3) still occur [10,11].2. Metabolism of VCM and genotoxicity
VCM is rapidly absorbed through the lungs and is
rapidly metabolized by the liver [1,12]. The metabolic
pathway of elimination of VCM is shown in Fig. 1 [1].
Chloroethylene oxide is a reactive intermediate metabo-
lite that is detoxiﬁed by conjugation with glutathione or
via aldehyde dehydrogenase [1]. However, chloroethyl-
ene oxide can also form DNA adducts that are muta-
genic [1]. VCM has been shown to be genotoxic in
in vivo studies in rats (summarized in Ref. [1]). VCM
vapour induces DNA strand breaks, sister chromatid
exchanges, micronucleus formation and other chromo-
somal aberrations. VCM is mutagenic in a number of
diﬀerent in vitro assays (summarized in Ref. [1]). Muta-tions of Ki-ras-2 and p53 genes have been described in
ASL; although it has been suggested that some of these
mutations may be characteristic of VCM exposure, the
same mutations have also been reported in other tumors
and in other ASL, in absence of any exposure to VCM
[13–17]. There is a characteristic mutation in the Ki-
ras-2 gene at codon 13 (GGC to GAC), or less com-
monly at codon 12 (also G to A) [13,14]. The mutations
in the p53 gene that are found in VCM-induced ASL
occur in several diﬀerent positions on the p53 gene
and do not appear to be characteristic for vinyl chloride
exposure [15,16]. The presence of these mutations in
non-tumour liver tissue has not been evaluated. This
would obviously be important to document as an impor-
tant piece of evidence as to whether VCM exposure
could lead to HCC. Although mutations in liver tissue
have not been investigated mutated Ki-ras and p53 pro-
teins have been discovered in the blood of workers
exposed to VCM [14,17–20]. In particular a dose–
response relationship was present between level of expo-
sure to VCM and likelihood of ﬁnding the mutated pro-
tein in blood. However, it is not yet clear whether these
changes are suﬃciently speciﬁc or sensitive that they can
be used to detect signiﬁcant exposure to VCM, or to
quantify degree of risk for ASL.3. Experimental evidence of liver injury from VCM
There have been numerous studies of exposure to
VCM in diﬀerent species of experimental animal.
VCM has been administered orally, by inhalation or
intra-tracheal administration or by intramuscular or
intraperitoneal administration, and by inhalation expo-
sure in the pregnant animals and the oﬀspring moni-
tored for tumour development. These studies have
consistently demonstrated the development of the histo-
logical changes described below, and the development of
angiosarcoma of the liver and other tissues. The devel-
opment of HCC has not been uniform. HCC was not
seen in mice exposed to VCM by inhalation at exposures
ranging from 50 to 10,000 ppm for periods exceeding
24 weeks [21–25]. HCC has been reported in rats
exposed to VCM by inhalation or by oral feeding [23–
28], but not when exposed by subcutaneous or intraperi-
toneal injection [23,29–31]. Doses up to 30,000 ppm for
52 weeks found only occasional HCC. Maltoni and
Cotti [30], did not ﬁnd a dose–response between VCM
and the development of HCC, but HCC only occurred
at a dose that was many multiples of what a human
might be exposed to. Drew et al. [25], described an
increased incidence of hepatic adenomas and HCC in
VCM-exposed rats, but there was no dose–response
relationship. Feron et al. [26,32] and Til et al. [31], also
described dose–response relationships between the
degree of exposure to VCM and the development of
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Fig. 1. The metabolic pathway of elimination of VCM.
1076 M. Sherman / Journal of Hepatology 51 (2009) 1074–1081HCC. However, once again, the doses at which HCC
developed were very much higher than would be
expected in VCM plants. Only in the oﬀspring of female
rats exposed during pregnancy was HCC found at
appreciable rates [30].4. Pathology
The pathology of VCM-induced liver injury has been
described in experimental animals and in humans [33–36]. The changes are similar. The brunt of the injury is
at the sinusoidal level but hepatocytes may also be
involved. There may be simple sinusoidal dilatation,
with or without endothelial cell hyperplasia. In milder
cases there is perisinusoidal and perivascular ﬁbrosis.
In more advanced cases there is periportal, portal and
subcapsular ﬁbrosis. Subcapsular ﬁbrosis in particular
is a characteristic of this kind of injury, and is similar
to that caused by thorotrast or arsenic. Ultimately, if
ﬁbrosis is extensive enough the ﬁbrosis coalesces so that
the appearances are typical of cirrhosis. Endothelial cell
Table 1
Cumulative exposures to VCM and the likelihood of HCC being present
[40]. Only at the highest exposure is the likelihood of HCC increased,
and this is based on only two subjects. There is no dose–response
relationship.
VCM exposure
(ppm years)
Number of
cases
Relative risk of
HCC (95%, CI)
0–734 3 1.0 (reference)
735–2379 2 3.02 (0.50–18.1)
2380–5188 1 2.47 (0.26–23.9)
5189–7531 1 5.33 (0.54–52.5)
>7532 2 RR not given (2.98–138)
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These may be pre-neoplastic changes, although it has
not been possible to study the sequential changes from
dysplasia to neoplasia. Hepatocyte nuclear changes sim-
ilar to dysplasia seen in other causes of cirrhosis may
also occur. This has been taken as evidence that VCM
can cause HCC. All these changes were described in
an era before hepatitis C, and in some cases, before even
hepatitis B was identiﬁed, so that at least some of the
changes might have been due to chronic viral hepatitis.
This is particularly true in cases coming from southern
Europe, where chronic viral hepatitis was prevalent.
The extensive sinusoidal ﬁbrosis has a clinical corre-
late in the development of non-cirrhotic portal hyperten-
sion. Patients can develop varices that can bleed,
splenomegaly and ascites despite the absence of
cirrhosis.5. Angiosarcoma of the liver
Angiosarcoma of the liver is a rare tumour, even in
VCM workers. It is this very rarity that allowed identi-
ﬁcation of the causal relationship with VCM, when
three cases were reported from a single plastics plant
[36]. Since then a number of studies have been con-
ducted, including large-scale epidemiologic surveys
[37–40] comparing all cause mortality and disease-spe-
ciﬁc mortality in VCM workers with regional mortality
results, to case-control studies using non-exposed work-
ers as controls [40,41].
There have been two large-scale multicentre epidemi-
ological studies of cancer and mortality risk in VCM
workers, one in North America and one in Europe. Peri-
odic updates of these series have also been published.
The North American study [39] included 37 plants with
10,173 workers. In the latest update the standardized
mortality ratio (SMR) from cancer of the liver and bil-
iary tract was 3.59 (95%, CI 2.84–4.46) [39]. The refer-
ence for SMR was the rate in the state in which the
plant occurred. Of the 80 deaths from primary liver can-
cer 48 were apparently due to angiosarcoma. The
SMR’s from primary liver cancers increased with
increasing duration of exposure. Death from angiosar-
coma was also associated with duration of exposure,
but the rarity of this disease in the general population
made development of SMR’s impossible.
In the European study originally published in 1986
and updated up to 1993–1997 [40] there were 19 facto-
ries and 12,700 male exposed workers. Reference rates
of SMR were national mortality rates for workers in
the diﬀerent countries. The SMR for primary liver can-
cer was 2.4 (95%, CI 1.8–3.14). Of the 71 cases of pri-
mary liver cancer there were 37 conﬁrmed cases of
ASL and 10 conﬁrmed cases of HCC. The cumulative
exposure estimates (Table 1) from this study did not sug-gest that there was a dose–response relationship between
exposure and the development of HCC.6. Vinyl chloride and HCC
The most up-to-date and most comprehensive analy-
ses is a pooled analyses of cohorts of VCMworkers from
plants in the USA and Europe [41]. The results from the
two large multicenter studies and the pooled meta-analy-
sis are presented in Table 2. This analysis includes more
than 22,000 workers with about 640,000 person years of
observations. In these two cohorts 1,778 cancer deaths
were observed, vs. 1829 expected, giving a standardized
mortality ratio of 0.97 (95%, CI 0.93–1.02), i.e., not statis-
tically diﬀerent. There were 71 conﬁrmed angiosarcomas
and 60 additional deaths from liver cancer vs. 44 expected
liver cancer deaths (SMR 1.35, 95%, CI 1.03–1.74), i.e.,
barely statistically signiﬁcant. Misclassiﬁcation, ascer-
tainment bias, and inadequate assessment of confound-
ing factors makes it likely that the minor increased risk
of liver cancer other thanASL that was found is spurious.
This meta-analysis conﬁrmed that there was an increase
in mortality from primary liver cancer and that ASL
was the most common form of primary liver cancer
[41]. The calculated SMR of 1.35 (95%, CI 1.04–1.77)
for liver cancer other than ASL is lower than the SMR
calculated in the two studies from which the meta-analy-
sis was derived. The original studies calculated the SMR
for all primary liver cancers, including angiosarcoma and
liver cancer other than ASL. However, in the meta-anal-
ysis using raw data from the two previous studies the
authors were able to subtract conﬁrmed angiosarcomas
from the total number of liver cancers and calculate the
SMR forHCC alone. These studies, coupled with the rar-
ity of ASL in the general population have been taken as
evidence that VCM does indeed cause ASL. Few would
argue with this conclusion, even though standardized
mortality rates could not be calculated.
The large-scale multicentre North American study
[39] did not provide data on the SMR for death from
HCC. In the European study [40] there were 10 con-
ﬁrmed cases of HCC. A further analysis suggested that
the risk of dying from HCC was signiﬁcantly associated
Table 2
Risk of primary liver cancer in VCM workers [6].
Site Number of
subjects
Study
population
Type of
cancer
SMR/RR/Hazard
ratio/Relative
risk (95%, CI)
Reference
population
Comment Reference
USA [39] 10,109 All exposed
VCM factory
workers
All primary
liver cancer
SMR 3.59 (2.84–4.46) State and
US population
Mundt et al. [39]
All primary
liver cancer
except
angiosarcoma
SMR 1.8 (1.3–2.5) Derived from
raw data by
Boﬀetta et al. [41]
Italy, Norway,
Sweden, UK [40]
12,700 All exposed
VCM factory
workers
All primary
liver cancer
SMR 2.4 (1.8–3.14) Country
population
Ward et al. [40]
1–9 years
of exposure
HCC Reference
10–16 years
of exposure
HR 6.94 (0.71–67.5)
17–20 years
of exposure
HR 12.6 (1.11–143)
21–25 HR 7.34 (0.44–122)
P26 HR 35.3 (3.34–377)
Cirrhosis SMR 0.77 (0.57–1.02)
Meta-analysis [41] 22,809 All exposed
VCM factory
workers
HCC SMR 1.35 (1.04–1.77)a Boﬀetta et al. [41]
a SMR of HCC only, exclusive of angiosarcoma.
Table 3
Cumulative exposure to VCM and the risk of developing cirrhosis (taken
from Ward et al. [40]). There does not appear to be a dose–response
relationship between exposure and cirrhosis.
1078 M. Sherman / Journal of Hepatology 51 (2009) 1074–1081with duration of exposure and for ever vs. never
exposed. This study found decreased mortality for cirr-
hosis, overall, although a trend with cumulative expo-
sure was observed. However, there did not appear to
be a correlation between cumulative exposure and death
rates from cirrhosis. A separate cohort study of workers
at one of the plants that contributed to this study also
found that there was an association between exposure
to VCM and mortality from HCC or cirrhosis [42].
Wong et al. [43,44] analyzed mortality in a cohort of
3293 male PVC workers, and found that there was an
increased SMR for malignant neoplasms of the liver
(SMR 1.78, 95%, CI 1.15–2.62). There were 25 deaths
from liver neoplasms, of which 5 were conﬁrmed as
HCC. An additional 5 had appropriate radiology with
an AFP >1000 lg/L. Therefore, only 40% of cases were
conﬁrmed as HCC, although death certiﬁcates suggested
that all were due to HCC. Thus, no deaths from ASL
were recorded. However, in Taiwan, where this study
was performed HCC is common, and in the absence of
histological proof patients dying a cancer death with a
mass in the liver would be assumed to have died of
HCC. Hence, absence of conﬁrmation in 60% of cases
makes these results uncertain.Cumulative exposure
(ppm years)
Number
of cases
Relative risk of
cirrhosis (95%, CI)
<524 8 1.0 (reference)
524–998 8 9.38 (3.52–25.0)
999–3429 9 4.01 (1.55–10.4)
3430–5148 8 9.77 (3.66–26.1)
>5149 9 8.28 (3.15–21.8)7. Vinyl chloride and cirrhosis
The IARC monograph on the carcinogenicity of
VCM takes for granted that exposure to VCM causescirrhosis, without examining the data. This association
is then used to support the argument that VCM also
causes HCC. Three publications examined the relation-
ship between VCM exposure and the presence of cirrho-
sis, all coming from European cohorts. Ward et al. [40],
in the large European multicenter study actually found
an overall decrease in deaths from cirrhosis in the
VCM-exposed workers. Cumulative VCM exposure
and the risk of having cirrhosis is shown in Table 3.
Mastrangelo et al. [42] retrospectively analyzed VCM
workers involved in a lawsuit. These cases were also
included in the European multicenter study. There were
643 workers, among whom 40 cases of cirrhosis were
identiﬁed either histologically or on biopsy. The authors
attempted to evaluate the eﬀect of multiple risk factors
on the development of HCC and cirrhosis. They exam-
ined three variables, VCM exposure (three strata),
M. Sherman / Journal of Hepatology 51 (2009) 1074–1081 1079alcohol consumption (three strata) and the presence of
absence of chronic viral hepatitis. They describe that
overall those with cirrhosis had a higher exposure to
VCM than those who did not, with an odds ratio of
1.37 (95%, CI 1.13–1.69). However, in looking at the
interaction of variables each cell contained 10 or fewer
cases, making the ﬁndings of an interaction unreliable,
even if statistically signiﬁcant. Since the cumulative
exposure is to a large extent a function of duration of
exposure, cumulative exposure is also a function of age.
Pirastu et al. [45] examined workers from the same
plant. It is not clear to what extent, if any, this cohort
overlapped with the previous cohort. They found an
increasing prevalence of cirrhosis with increasing expo-
sure to VCM. However, the same objection applies as
with the previous study.
Others have used ﬁbrosis as an endpoint, but did not
use biopsy to make the diagnosis of ﬁbrosis. Hsieh et al.
[46] attempted to evaluate the eﬀect of CYP2E1 poly-
morphisms on the development of liver ﬁbrosis in those
exposed to VCM. Fibrosis was diagnosed by ultra-
sound. They described that there was a relationship
between VCM exposure and the diagnosis of ﬁbrosis.
Hsiao et al. [47] and Maroni et al. [48] again using ultra-
sound to diagnosis ﬁbrosis came to a similar conclusion.
However, as all hepatologists know, ultrasound is an
inappropriate tool to diagnose ﬁbrosis. Ultrasound can
only diagnose the presence of ﬁbrosis with any degree
of certainty when cirrhotic nodules can be detected, indi-
cating relatively late-stage disease. Lesser degrees of
ﬁbrosis cannot be diagnosed by ultrasonography. There-
fore all studies using ultrasound to diagnose ﬁbrosis are
unreliable.8. Evaluation of the evidence
Thus, the evidence in favour of VCM as a cause of
HCC and cirrhosis rests upon retrospective studies that
showed in some cases an increased mortality from liver
cancer other than ASL above what would have been
expected for a similar population, and upon some stud-
ies that showed a dose–response relationship between
the degree of exposure to VCM and the likelihood of
dying of HCC.
All these studies are open to criticism on a number of
diﬀerent grounds. The ﬁrst is ascertainment bias. This is
the bias that is introduced when the disease of interest
has not been diagnosed conclusively. Thus the question
arises: how certain can we be sure that those labeled as
HCC were indeed HCC and not some other liver cancer
or ASL, and how certain can we be that those labeled as
cirrhosis did indeed have this condition?
Most of the patients included in these studies died
before 1995, and many were diagnosed in the 1960s
and 1970s. Ultrasound and CT scanning were onlyintroduced in the 1970s. Prior to that the diagnosis of
HCC rested upon autopsy data, biopsy data, angiogra-
phy or a diagnostically elevated AFP. In the absence
of such conﬁrmation a death certiﬁcate diagnosis of
HCC is unreliable. In the absence of histologic or radio-
graphic proof, patients presenting with liver failure and
what seemed to be a mass in the liver would be much
more likely to be labeled as HCC than angiosarcoma,
since angiosarcoma was a rare tumour, whereas HCC,
although not common, was much more frequent than
ASL. This criticism applies doubly to the Taiwan study
that found all the primary liver cancers to be HCC.
HCC is one of the most common cancers in Taiwan.
Thus, in the absence of histology primary cancers of
the liver are much more likely to be called HCC than
ASL, and it is conceivable that at least some of the can-
cers in this study were not HCC. Thus ascertainment
bias may have inﬂuenced the apparent incidence of
HCC. The meta-analysis, looking only at cases not con-
ﬁrmed as ASL found that VCM was only marginally sig-
niﬁcantly associated with liver cancer other than ASL.
Given the small overall numbers of cases (10 cases) mis-
classiﬁcation of only a few liver tumours would change a
non-signiﬁcant association to a signiﬁcant association.
Ascertainment bias may also have inﬂuenced the
apparent mortality from cirrhosis. First, not all studies
found an increase in cirrhosis deaths. In fact the meta-
analysis found a lower than expected mortality from cir-
rhosis. But it is important to also consider that VCM
causes non-cirrhotic portal hypertension. In the 1960s
and 1970s the diagnosis of cirrhosis was usually made
clinically and referred to a syndrome of ascites, variceal
bleeding, hepatic encephalopathy and possibly jaundice.
In the absence of liver biopsy data, and in the era in
which these patients were aﬀected it is quite possible that
at least some of the patients diagnosed with cirrhosis
actually had non-cirrhotic portal hypertension. Since
the number of patients diagnosed with cirrhosis was
not large, misclassiﬁcation of only a few cases of non-
cirrhotic portal hypertension as cirrhosis would alter
the statistical signiﬁcance of the association between
VCM and cirrhosis from non-signiﬁcant to signiﬁcant.
This may seem like a semantic argument, whether
VCM causes cirrhosis or not, but it has more signiﬁ-
cance than simple semantics. If these patients truly
had cirrhosis then it could be argued that cirrhosis is a
precursor to HCC, and therefore the development of cir-
rhosis is an argument in favour of the association
between VCM and HCC. If, on the other hand, the clin-
ical presentation was due to non-cirrhotic portal hyper-
tension the strength of this argument is reduced.
Ascertainment bias may be very important in assessing
the relationship between cirrhosis and VCM.
Thus, the statistical association between VCM and
the development of HCC would seem to be less certain
than presented by IARC.
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tionship between VCM and HCC. If the dose–response
relationship is real, this is indeed support for a causal
relationship association. However, the European study
[40] that evaluated the dose–response relationship
included only 10 cases of HCC stratiﬁed into 4 dose cat-
egories. Thus each dose category cannot have contained
more than 2–3 subjects. Therefore, although there seems
to be a trend towards a higher HCC death rate with
increasing dose, the possibility of a type I error is very
high.
Finally, patients included in the multicenter studies
were largely diagnosed before testing for viral hepatitis
was available. Testing for hepatitis B was introduced
in the late 1960s and for hepatitis C only in 1990. Thus,
the contribution of these infections to the development
of HCC cannot be assessed. Standardized mortality
rates assume that the population being studied i.e.,
VCM workers, would have the same prevalence of con-
founding diseases as the regional population. Case-con-
trol studies make a similar assumption when e.g., oﬃce
staﬀ is used as controls. However, these assumptions
have not been tested. For example, oﬃce workers may
have a diﬀerent level of education than factory ﬂoor
workers, and since hepatitis C is associated with socio-
economic status the oﬃce workers may not be a suitable
control for e.g., HCC mortality. The prevalence of viral
hepatitis in VCM workers may not be the same as in the
local general population for similar reasons. The level of
alcohol consumption may also be diﬀerent between fac-
tory ﬂoor workers and oﬃce workers or regional
controls.9. Summary
To conclude, although a reputable and inﬂuential
organization (IARC) has indicated that VCM does
cause HCC, the basis for these statements seems to be
less than solid. Others have raised this issue, suggesting
that apart from angiosarcoma there is no evidence that
chronic exposure to VCM causes any other cancer
[49,50]. More recent analyses don’t really contradict
this. It is not possible to say the there is no association,
but to this reader the evidence is less than convincing.
Perhaps the most appropriate statement would be that
the proposition that exposure to VCM causes HCC
remains to be proven.References
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